Initial dosing regimen of vancomycin to achieve early therapeutic plasma concentration in critically ill patients with MRSA infection based on APACHE II score

[1]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  G. Drusano,et al.  Vancomycin: we can't get there from here. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Arthur S Slutsky,et al.  Sepsis and endothelial permeability. , 2010, The New England journal of medicine.

[5]  M. Falagas,et al.  Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care. , 2010, Minerva anestesiologica.

[6]  Frédérique Jacobs,et al.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock , 2010, Critical care.

[7]  J. Vincent,et al.  Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock , 2010, Critical care.

[8]  Jordi Rello,et al.  International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.

[9]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[10]  Martin Brunner,et al.  Impaired target site penetration of &bgr; -lactams may account for therapeutic failure in patients with septic shock , 2001, Critical care medicine.

[11]  G Sherman,et al.  The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. , 2000, Chest.

[12]  G Sherman,et al.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.

[13]  M. Lamy,et al.  Sepsis and serum cytokine concentrations. , 1997, Critical care medicine.

[14]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[15]  J. Rotschafer,et al.  Vancomycin pharmacokinetics in patients with various degrees of renal function , 1988, Antimicrobial Agents and Chemotherapy.

[16]  J. L. Gall,et al.  APACHE II--a severity of disease classification system. , 1986, Critical care medicine.

[17]  G. Matzke,et al.  Clinical Pharmacokinetics of Vancomycin , 1986, Clinical pharmacokinetics.

[18]  Y. Nishi,et al.  Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[19]  J. Roberts,et al.  Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. , 2011, Critical care clinics.

[20]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Vincent,et al.  Researchβ-lactam concentrations in the early phase of severe sepsis and septic shock , 2010 .

[22]  J. Roberts,et al.  Antibacterial Dosing in Intensive Care , 2006, Clinical pharmacokinetics.